Comments on avelox's Journal

Generic Name: Moxifloxacin hydrochloride Product Name: Avelox Indication of Avelox: Used in adults for the treatment of infections caused by micro-organisms susceptible to Moxifloxacin. Including: Acute bacterial sinusitis; community-acquired pneumonia; acute exacerbations of chronic bronchitis. Intravenous use in adults is indicated for the treatment of moderate and severe infections caused by susceptible pathogens. Including: Community-acquired pneumonia; acute exacerbations of chronic bronchitis (where the responsible organisms display proven resistance to, or where there is intolerance to other antibiotics) Action of Avelox: Moxifloxacin in a synthetic, broad spectrum quinolone antibiotic with bactericidal action. The bactericidal activity results from an inhibition of bacterial DNA repair, transcription, repair and recombination, and is concentration dependent. Moxifloxacin shows in vitro and clinical activity against most strains of the following pathogens: S.pneumoniae, S.aureus, H.influenzae, H.parainfluenzae, K.pneumoniae, M.catarrhalis, C.pneumoniae, M.pneumoniae. Moxifloxacin is rapidly and almost completely absorbed from the gut following oral administration. Food does not effect the degree of absorption. Plasma concentrations are dose proportional. Mean elimination half life is 11-13 hours, with steady state achieved after about 3 days following a 400 mg once daily dose regimen. Moxifloxacin is mainly bound to serum albumin, and distributes widely through the body, including to saliva, nasal and bronchial secretions, and sinus mucosa. Elimination rates from tissues correlated with elimination from plasma. Moxifloxacin is metabolised in the liver (the cytochrome P450 system is not involved). Most of the metabolised drug is excreted in the faeces, some is excreted in the urine. Dose Advice of Avelox: Acute bacterial sinusitis: 400 mg orally, once daily, for 10 days. Acute bacterial exacerbation of chronic bronchitis: 400 mg orally, once daily, for 5 days OR 400 mg sequential intravenously/orally for 5 days. Community acquired pneumonia: 400 mg orally, once daily, for 10 days OR 400 mg sequential intravenously/orally for 7-14 days. Elderly, Patients with Renal or Hepatic Impairment: Dosage adjustment is not required in elderly patients, patients with renal impairment, or patients with mild/moderate hepatic impairment. The use of moxifloxacin in patients with severe hepatic impairment has not been sufficiently studied. Children: The use of moxifloxacin is not recommended in the paediatric population. Use in pregnant or lactating women: The use of moxifloxacin in pregnant or breastfeeding women is not recommended. Common side effects of Avelox: Abdominal pain, nausea, diarrhoea, vomiting, dyspepsia, abnormal liver function tests. Headache, dizziness. Injection site reaction. Uncommon side effects of Avelox: Pain, malaise, arthralgia, myalgia Insomnia, nervousness, anxiety, tremor, vertigo. Tachycardia, palpitations, hypertension, shortness of breath, oedema. Rash, pruritus, sweating. Moniliasis, vaginitis. Pseudomembranous colitis For further information talk to your doctor.